CassandraBio
Pipeline dossier

NIH & clinical-trial pipeline signals for AMGEN INC (AMGN)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for AMGN, mapped to public ticker AMGN (CIK 0000318154). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →
Trial → FilingAMGN35% conf

AMGEN INC (AMGN) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)
trial ↗filings ↗
Trial → FilingAMGN35% conf

AMGEN INC (AMGN) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)
trial ↗filings ↗
Trial → FilingAMGN35% conf

AMGEN INC (AMGN) — PHASE1 protocol updated 2 days ago

Upstream (observed)
Clinical trial status (PHASE1) — A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)
trial ↗filings ↗

Recent SEC 8-K filings

JSON API for this entity →